Cognitive effects of adjunctive 24-weeks Rivastigmine treatment to antipsychotics in schizophrenia: A randomized, placebo-controlled, double-blind investigation

Schizophrenia Research

Volumn 85, Issue 1-3, 2006, Pages 73-83

  Sharma, Tonmoy ^a   Reed, Catherine ^b   Aasen, Ingrid ^b   Kumari, Veena ^b  

^a NEUROSCIENCE RESEARCH CENTRE   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Cholinergics; Cognitive enhancement; Nicotine; Schizophrenia

Indexed keywords

NEUROLEPTIC AGENT; RIVASTIGMINE;

ADD ON THERAPY; ADULT; AGED; ARTICLE; ATTENTION; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; MALE; PRIORITY JOURNAL; PSYCHOMETRY; PSYCHOMOTOR PERFORMANCE; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; SPATIAL MEMORY; TASK PERFORMANCE; TREATMENT OUTCOME; VERBAL BEHAVIOR; VERBAL MEMORY; WORKING MEMORY;

ADULT; ANTIPSYCHOTIC AGENTS; CHOLINESTERASE INHIBITORS; COGNITION DISORDERS; DOUBLE-BLIND METHOD; FEMALE; GANGLIONIC STIMULANTS; HUMANS; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; NICOTINE; PHENYLCARBAMATES; PHYSOSTIGMINE; PSYCHOMOTOR PERFORMANCE; SCHIZOPHRENIA; SEVERITY OF ILLNESS INDEX; VERBAL BEHAVIOR;

EID: 33745378627     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.schres.2006.03.037     Document Type: Article

References (59)

1. Aasen I., Kumari V., and Sharma T. Effects of Rivastigmine on attention in schizophrenia. J. Clin. Psychopharmacol. 25 4 (2005) 311-317
2. Addington J., and Addington D. Neurocognitive and social functioning in schizophrenia. Schizophr. Bull. 25 1 (1999) 173-182
3. Arnt J., and Skarsfeldt T. Do novel antipsychotics have similar pharmacological characteristics? A review. Neuropsychopharmacology 18 (1998) 63-101
4. Benton A.L., Hamsher K., Varney N.R., and Spreen O. Contributions to Neuropsychological Assessment (1983), Oxford University Press, New York
5. Birks J., Grimley E.J., Iakovidou V., and Tsolaki M. Rivastigmine for Alzheimer's disease. Cochrane Database Syst. Rev. 4 (2000) (CD001191)
6. Buchanan W., Summerfelt A., Tek C., and Gold J. An open-labeled trial of adjunctive donepezil for cognitive impairments in patients with schizophrenia. Schizophr. Res. 59 (2003) 29-33
7. Cornblatt B.A., and Keilp J.G. Impaired attention, genetics, and the pathophysiology of schizophrenia. Schizophr. Bull. 20 (1994) 31-46
8. Decker M.W., and McGaugh J.L. The role of interactions between the cholinergic system and other neuromodulatory systems in learning and memory. Synapse 7 2 (1991) 151-168
9. Delis D.C., Kramer J.H., Kaplan E., and Ober B. California Verbal Learning Test Manual. Research Edition (1987), The Psychological Corporation, New York
10. Doody R.S. Current treatments for Alzheimer's disease: cholinesterase inhibitors. J. Clin. Psychiatry 64 Suppl. 9 (2003) 11-17
11. Ettinger U., Kumari V., Zachariah E., Galea A., Crawford T.J., Corr P.J., Taylor D., Das M., and Sharma T. Effects of procyclidine on eye movements in schizophrenia. Neuropsychopharmacology 28 (2003) 2199-2208
12. Evans J.D., Heaton R.K., Paulsen J.S., Palmer B.W., Patterson T., and Jeste D.V. The relationship of neuropsychological abilities to specific domains of functional capacity in older schizophrenia patients. Biol. Psychiatry 53 5 (2003) 422-430
13. Farlow M.R., Small G.W., Quarg P., and Krause A. Efficacy of Rivastigmine in Alzheimer's disease patients with rapid disease progression: results of a meta-analysis. Dement. Geriatr. Cogn. Disord. 20 2-3 (2005) 192-197
14. First M.B., Spitzer R.L., Gibbon M., and Williams J.B.W. Structured Clinical Interview for DSM-IV Axis I Disorders, Patient Edition (SCID-P), Version 2 (1995), New York State Psychiatric Institute, Biometrics Research, New York
15. Friedman J.I. Cholinergic targets for cognitive enhancement in schizophrenia: focus on cholinesterase inhibitors and muscarinic agonists. Psychopharmacology 174 (2004) 45-53
16. Friedman J.I., Temporini H., and Davis K.L. Pharmacologic strategies for augmenting cognitive performance in schizophrenia. Biol. Psychiatry 45 (1999) 1-16
17. Friedman J.I., Adler D.N., Howanitz E., Harvey P.D., Brenner G., Temporini H., White L., Parrella M., and Davis K.L. A double-blind placebo-controlled trial of donepezil adjunctive treatment to risperidone for the cognitive impairment of schizophrenia. Biol. Psychiatry 51 (2002) 349-357
18. Giacobini E. Cholinergic function and Alzheimer's disease. Int. J. Geriatr. Psychiatry 18 Suppl. 1 (2003) S1-S5
19. Green M.F. What are the functional consequences of neurocognitive deficits in schizophrenia?. Am. J. Psychiatry 153 (1996) 321-330
20. In: Guy W. (Ed). ECCDEU Assessment Manual for Psychopharmacology (revised). DHEW Publication No. (ADM) (1976), National Institutes of Mental Health, Rockville, MD 76-338
21. Halstead W.C. Brain and Cognition (1947), University of Chicago Press, Chicago
22. Harry R.D., and Zakzanis K.K. A comparison of donepezil and galantamine in the treatment of cognitive symptoms of Alzheimer's disease: a meta-analysis. Hum. Psychopharmacol. 20 3 (2005) 183-187
23. Harvey P.D., Green M.F., Keefe R.S., and Velligan D.I. Cognitive functioning in schizophrenia: a consensus statement on its role in the definition and evaluation of effective treatments for the illness. J. Clin. Psychiatry 65 3 (2004) 361-372
24. Heaton R.K. Wisconsin Card Sorting Test: Computer Version-2 Research Edition (1993), Psychological Assessment Resources Inc
25. Howard A.K., Thornton A.E., Altman S., and Honer W.G. Donepezil for memory dysfunction in schizophrenia. J. Psychopharmacol. 16 3 (2002) 267-270
26. Hughes J.R., Hatsukami D.K., Mitchell J.E., and Dahlgren L.A. Prevalence of smoking among psychiatric disorders. Am. J. Psychiatry 143 (1986) 993-997
27. Hughes C., Kumari V., Soni W., Das M., Binneman B., Drozd S., O'Neil S., Mathew V., and Sharma T. Longitudinal study of symptoms and cognitive function in chronic schizophrenia. Schizophr. Res. 59 2-3 (2003) 137-146
28. Jann M.W. Rivastigmine, a new-generation cholinesterase inhibitor for the treatment of Alzheimer's disease. Pharmacotherapy 20 1 (2000) 1-12
29. Kay S.R., Fiszbein P.S., and Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. 13 (1987) 261-276
30. Keefe R.S.E., Roitman S.E., Harvey P.D., Blum C.S., DuPre R.L., Prieto D.M., Davidson M., and Davis K.L. A pen-and-paper human analogue of a monkey prefrontal cortex activation task: spatial working memory in patients with schizophrenia. Schizophr. Res. 17 (1995) 25-33
31. Kumari V., and Postma P. Nicotine use in schizophrenia: the self-medication hypotheses. Neurosci. Biobehav. Rev. 29 6 (2005) 1021-1034
32. Kumari V., Zachariah E., Mehrotra R., Taylor D., and Sharma T. Effects of procyclidine on prepulse inhibition of the acoustic startle response in healthy human volunteers. Psychopharmacology 154 (2001) 221-229
33. Kumari V., Zachariah E., Galea A., Jones H., Das M., Mehrotra R., Taylor D., and Sharma T. Effects of acute procyclidine administration on prepulse inhibition of the startle response in schizophrenia: a double blind, placebo-controlled study. J. Psychopharmacol. 17 1 (2003) 89-95
34. Kumari V., Aasen I., Ffytche D., Willams S.C.R., and Sharma T. Neural correlates of adjunctive Rivastigmine treatment to antipsychotics in schizophrenia: a randomised, placebo-controlled, double-blind fMRI study. NeuroImage 29 2 (2006) 545-556
35. Lehman A.F., Carpenter Jr. W.T., Goldman H.H., and Steinwachs D.M. Treatment outcomes in schizophrenia: implications for practice, policy, and research. Schizophr. Bull. 21 (1995) 669-675
36. Lenzi A., Maltinti E., Poggi E., Fabrizio L., and Coli E. Effects of Rivastigmine on cognitive function and quality of life in patients with schizophrenia. Clin. Neuropharmacol. 26 6 (2003) 317-321
37. MacEwan G.W., Ehmann T.S., Khanbhai I., and Wrixon C. Donepezil in schizophrenia-is it helpful? An experimental design case study. Acta Psychiatr. Scand. 104 (2001) 469-472
38. Maelicke A., Samochocki M., Jostock R., Fehrenbacher A., Ludwig J., Albuquerque E.X., and Zerlin M. Allosteric sensitization of nicotinic receptors by galantamine, a new treatment strategy for Alzheimer's disease. Biol. Psychiatry 49 (2001) 279-288
39. Mandel R.J., Chen A.D., Connor D.J., and Thal L.J. Continuous physostigmine infusion in rats with excitotoxic lesions of the nucleus basalis magnocellularis: effects on performance in the water maze task and cortical cholinergic markers. J. Pharmacol. Exp. Ther. 251 2 (1989) 612-619
40. Morris R.G. The Computerised Trail Making Test (1995), Institute of Psychiatry, London
41. Nahas Z., George M.S., Horner M.D., Markowitz J.S., Li X., Lorberbaum J.P., Owens S.D., McGurk S., DeVane L., and Risch S.C. Augmenting atypical antipsychotics with a cognitive enhancer (donepezil) improves regional brain activity in schizophrenia patients: a pilot double-blind placebo controlled BOLD fMRI study. Neurocase 9 (2003) 274-282
42. Nelson, H.E., Willison, J.R., 1991. National Adult Reading Test (Part II): Test manual. NFER-NELSON, Windsor.
43. Polinsky R.J. Clinical pharmacology of Rivastigmine: a new-generation acetylcholinesterase inhibitor for the treatment of Alzheimer's disease. Clin. Ther. 20 (1998) 634-647
44. Powchik P., Davidson M., Haroutunian V., Gabriel S.M., Purohit D.P., Perl D.P., Harvey P.D., and Davis K.L. Postmortem studies in schizophrenia. Schizophr. Bull. 24 3 (1998) 325-341
45. Riley E.M., McGovern D., Mockler D., Doku V.C., Oceallaigh S., Fannon D.G., Tennakoon L., Santamaria M., Soni W., Morris R.G., and Sharma T. Neuropsychological functioning in first-episode psychosis-evidence of specific deficits. Schizophr. Res. 43 (2000) 47-55
46. Risch S.C., McGurk S., Horner M.D., Nahas Z., Owens S.D., Molloy M., Gilliard C., Christie S., Markowitz J.S., DeVane C.L., Mintzer J., and George M.S. A double-blind placebo-controlled case study of the use of donepezil to improve cognition in a schizoaffective disorder patient: functional MRI correlates. Neurocase 7 2 (2001) 105-110
47. Rund B.R. A review of longitudinal studies of cognitive functions in schizophrenia patients. Schizophr. Bull. 24 (1998) 425-435
48. Schrattenholz A., Pereira E.F.R., Roth U., Weber K.H., Albuquerque E.X., and Maelicke A. Agonist responses of neuronal nicotinic receptors are potentiated by a novel class of allosterically acting ligands. Mol. Pharmacol. 46 (1996) 1-6
49. Sharma T., and Harvey P. Cognition in Schizophrenia: Impairments: Importance, and Treatment Strategies (2000), Oxford University Press
50. Shirazi-Southall S., Rodriguez D.E., and Nomikos G.G. Effects of typical and atypical antipsychotics and receptor selective compounds on acetylcholine efflux in the hippocampus of the rat. Neuropsychopharmacology 26 (2002) 583-594
51. Strauss M.E., Reynolds K.S., Jayaram G., and Tune L.E. Effects of anticholinergic medication on memory in schizophrenia. Schizophr. Res. 3 (1990) 127-129
52. Stryjer R., Bar F., Strous R.D., Baruch Y., and Rabey J.M. Donepezil management of schizophrenia with associated dementia. J. Clin. Psychopharmacol. 22 (2002) 226-229
53. Stryjer R., Strous R.D., Bar F., Werber E., Shaked G., Buhiri Y., Kotler M., Weizman A., and Rabey J.M. Beneficial effect of donepezil augmentation for the management of comorbid schizophrenia and dementia. Clin. Neuropharmacol. 26 (2003) 12-17
54. Terry Jr. A.V., and Buccafusco J.J. The cholinergic hypothesis of age and Alzheimer's disease-related cognitive deficits: recent challenges and their implications for novel drug development. J. Pharmacol. Exp. Ther. 306 3 (2003) 821-827
55. Tugal O., Yazici K.M., Anil Yagcioglu A.E., and Gogus A. A double-blind, placebo controlled, cross-over trial of adjunctive donepezil for cognitive impairment in schizophrenia. Int. J. Neuropsychopharmacol. 7 2 (2004) 117-123
56. Velligan D.I., Mahurin R.K., Diamond P.L., Hazleton B.C., Stacey L.E., and Miller A.L. The functional significance of symptomatology and cognitive function in schizophrenia. Schizophr. Res. 25 (1997) 21-31
57. Wechsler D. Weschsler Adult Intelligence Scale-III (1997), The Psychological Corporation, San Antonio, TX
58. Williams B.R., Nazarians A., and Gill M.A. A review of Rivastigmine: a reversible cholinesterase inhibitor. Clin. Ther. 25 6 (2003) 1634-1653
59. Zachariah E., Kumari V., Galea A., Das M., Mehrotra R., Taylor D., Ruprah M., and Sharma T. Effects of oral procyclidine administration on cognitive functions in healthy subjects: Implications for schizophrenia. J. Clin. Psychopharmacol. 22 2 (2002) 224-226